- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06339567
Evaluation of the Venous Thrombotic Biological Profile of Different PCOS Phenotypes: French Cross-sectional Study (Hemo-PCOS)
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder of women of childbearing age. PCOS can be individualized into several phenotypes, taking into account in particular the presence of hyperandrogenism, insulin resistance and BMI. Hyperandrogenism and insulin resistance appear to be important factors in the development of cardiovascular cardiovascular disease. In addition, patients frequently use anti-androgenic and/or contraceptive treatments contraceptives, such as combined hormonal contraception (CHC), the use of which is associated with an increased cardiovascular and thrombo and venous thrombosis (VTE). A meta-analysis published in 2020 by Gariani et al.
based on three large studies, estimated the risk of VTE in women with PCOS after adjustment for obesity and hormone therapy. This risk was significantly higher compared with women without PCOS (pooled OR 1.89, CI95% 1.60-2.24). No study has looked specifically investigated the risk of VTE according to different PCOS phenotypes. Such data would be very useful in clinical practice, as it would enable monitoring, contraceptive treatment and anti-androgenic anti-androgen treatment according to the PCOS phenotype, while limiting risks. Assessing the differences PCOS phenotypes is limited by the large sample size required. required. VTE is a rare event in women of childbearing age, and the number of PCOS phenotypes is high.
PCOS phenotypes. Intermediate markers of VTE risk are used in these situations. These markers are thrombin generation tests (notably ETP) and their sensitivity to activated protein C (nAPCsr) and thrombomodulin (nTMsr), as well as sex-hormone binding globulin (SHBG).
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Justine Hugon Rodin, MD
- Phone Number: +33144127883
- Email: jhugon@ghpsj.fr
Study Contact Backup
- Name: Hélène Beaussier, pharmaD
- Email: hbeaussier@ghpsj.fr
Study Locations
-
-
-
Paris, France
- Recruiting
- Hopital Paris Saint Joseph
-
Contact:
- Hélène Beaussier, pharmaD
- Email: hbeaussier@ghpsj.fr
-
Contact:
- Juliette COURTIADE MAHLER
- Email: jcourtiade@ghpsj.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Be between 18 and 35 years of age at the time of inclusion;
- Able to give non-opposition
- Strong suspicion of PCOS according to 2023 recommendations
- Have stopped hormonal contraception for at least 3 months or insulin-sensitizing treatment for at least 3 months.
- Fasting for at least 12 hours.
- Be affiliated to a health insurance scheme.
- French-speaking
Exclusion Criteria:
- Already included in a type 1 interventional research protocol (RIPH1).
- Be under guardianship or curatorship
- Deprived of liberty
- Under court protection
- Pregnant (positive urine or blood pregnancy test), or within 3 months of post-partum or post abortum, or breastfeeding (or within 3 months of weaning)
- Using hormonal contraception or insulin-sensitizing therapy (a wash-out of at least 3 months before inclusion).
- Have a personal history of VTE or known thrombophilia.
- Current anticoagulant or antiaggregant treatment or treatment stopped less than one month before inclusion.
- Have a severe personal medical history in the previous 6 weeks (fracture, infection, hospitalization, surgery, cardiovascular event, cancer).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Thrombotic profil
|
several thrombotic biological marker will be dosed in blood.
(C protein, S protein, CRP us, Factor VIII, TFPI , nAPCsr, SHBG, nTMsr)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
biological procoagulant profile
Time Frame: one year
|
Evaluation of the biological procoagulant profile in women of childbearing age with PCOS, in relation to the presence or absence of insulin resistance, by comparing FTE levels between women with PCOS and women without PCOS.
the presence or absence of insulin resistance, by comparing ETP levels between women with PCOS without and with insulin resistance
|
one year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Insuline resistance and weight
Time Frame: 1 year
|
Estimate the prevalence of overweight, obesity, and insulin resistance in women with with PCOS
|
1 year
|
comparison of procoagulant profile depending on insulin resistance
Time Frame: 1 year
|
comparison of procoagulant biomarker for women with or without insulin resistance
|
1 year
|
comparison of procoagulant profile depending on hyperangrogenism
Time Frame: 1 year
|
comparison of procoagulant biomarker for women with or without hyperangrogenism
|
1 year
|
comparison of procoagulant profile depending on PCOS phenotype
Time Frame: 1 year
|
comparison of procoagulant biomarker depending on PCOS phenotype
|
1 year
|
comparison of procoagulant profile depending on AMH Rate
Time Frame: 1 year
|
comparison of procoagulant biomarker depending on AMH Rate
|
1 year
|
comparison of QoL score depending on PCOS phenotype
Time Frame: 1 year
|
comparison of PCOS-QoL, SF36 and HADS scores depending on PCOS phenotype
|
1 year
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 671_Hemo-PCOS
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Polycystic Ovary Syndrome
-
Cairo UniversityCompleted
-
Alexandria UniversityRecruitingPolycystic Ovary Syndrome (PCOS)Egypt
-
Saudi German Hospital - MadinahCompletedPolycystic Ovary Syndrome (PCOS)Saudi Arabia
-
University of CopenhagenCompletedPolycystic Ovary Syndrome (PCOS)Denmark
-
Odense University HospitalCompleted
-
Poznan University of Medical SciencesUniversity of California, DavisUnknownPolycystic Ovary Syndrome (PCOS)Poland
-
Mansoura UniversityNot yet recruitingPCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries
-
Assaf-Harofeh Medical CenterUnknownInfertility | Polycystic OvariesIsrael
-
Riphah International UniversityCompleted
-
Dexa Medica GroupCompletedPolycystic Ovary Syndrome (PCOS)Indonesia
Clinical Trials on Thrombotic profile
-
Assistance Publique Hopitaux De MarseilleNot yet recruiting
-
Universidad Peruana Cayetano HerediaInter-American Development BankCompletedQuality of Health Care
-
Riyadh Colleges of Dentistry and PharmacyCompletedCerebral Palsy | Dental DiseasesSaudi Arabia
-
Ryazan State Medical UniversityCompletedThrombosis | Venous Thromboembolism | covid19Russian Federation
-
East and North Hertfordshire NHS TrustLiverpool Heart and Chest Hospital NHS Foundation TrustRecruiting
-
University of SalamancaCompletedBone Loss | Dental Implant | Partial-edentulism | Soft TissueSpain
-
Christopher BarwaczCompletedEsthetics, Dental | Dental Implant, Single-ToothUnited States
-
Centre Hospitalier Intercommunal de Toulon La Seyne...Assistance Publique Hopitaux De Marseille; F-CRIN INNOVTE Research NetworkRecruiting
-
Gazi UniversityRecruitingEosinophilic Esophagitis | Sensory DisorderTurkey
-
Lena BornhoftRegion Västra Götaland, Sweden; Region Värmland, SwedenCompletedLifestyle Risk ReductionSweden